Abstract: This disclosure pertains to methods of treating prostate cancer in a subject in need thereof, including, for example, metastatic prostate cancer, castrate-resistant prostate cancer, and metastatic castrate-resistant prostate cancer, wherein the method comprises administering to the subject a therapeutically effective amount of Compound A, or a pharmaceutically acceptable salt thereof, and further comprises a step of discontinuing or reducing the administration of a CYP3A inhibitor or inducer, an efflux transporter substrate or inhibitor, or an uptake transporter substrate or inhibitor, to the subject prior to initiating administration of Compound A or the pharmaceutically acceptable salt thereof.

Abstract: This application is directed to controlling the illumination efficiency of a light emitting diode (LED) operation system, which includes an LED module and a current source. A power supply is configured to provide a configurable drive voltage. The LED module is coupled to the power supply interface and configured to be driven by the configurable drive voltage. The current source is (i) coupled to the power supply interface via the LED module and (ii) configured to stabilize a drive current of the LED module dynamically at a target drive current and hold an illumination efficiency of an LED operation system above a target efficiency level. In some embodiments, the current source includes a drive transistor coupled in series with the LED module. The current source is configured to hold the illumination efficiency of the LED operation system by controlling the drive transistor to operate in a linear region.

Abstract: A protein inhibitor or degrading agent, a pharmaceutical composition comprising same and a pharmaceutical use. Provided are a compound represented by general formula (I), and a pharmaceutical composition containing same. Also disclosed are an application of the compound of the general formula as a protein inhibitor and/or a protein degrading agent and a pharmaceutical use.

Abstract: An inspection device for use in a fluid container having at least an opening includes a housing sized to fit through the opening. The housing has at least two fluid flow channels extending therethrough, each having an inlet and an outlet, and a pump maintained in the housing within each fluid flow channel. The pumps are selectively controlled to maneuver the housing within the fluid container. The inspection device continues with a method of in-situ inspection of a container having at least one opening to receive a fluid, that includes up-loading a virtual model of the container into a computer, inserting the device into the container, generating a position signal by the device and receiving the position signal on a computer. A virtual image of the device in the virtual model of the container is generated to determine an actual position of the device within the container.

Abstract: The invention provides novel Fc-fusion proteins of interferon tau and compositions thereof, methods of their preparation and therapeutic use thereof in treating coronavirus (e.g., COVID-19 virus/SARS-CoV-2 and hCoV229E) viral infections, and related diseases and conditions.

Abstract: The invention generally relates to novel therapeutic uses of interferon tau as an antiviral agent. More particularly, the invention provides novel compositions of interferon tau and methods of therapeutic use thereof in treating viral infections and related diseases and conditions.

Abstract: The invention provides novel PEGylated interferon tau and therapeutic uses thereof. More particularly, the invention provides novel PEGylated interferon tau compositions, methods of their preparation, and methods of therapeutic use thereof in treating viral infections (e.g., coronavirus or flavivirus infections) and various other diseases and conditions.

Abstract: The present application is directed to an electrical system including a housing configured to hold electrical components within an internal volume. In one aspect the electrical system is a power transformer. A sensor is mounted to the housing and is configured to sense a parameter associated with one or more electrical components during operation of the electrical system. A control system including a communication unit and a data processing unit is operable for analyzing the sensed parameter and comparing the sensed parameter to a predetermined minimum or maximum threshold value.

Abstract: The present invention relates to a compound of formula (X) or a tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate thereof, and a pharmaceutical composition containing the compound and a use.

Abstract: The invention relates to (S)-6-((1 R,2E,4E,8E,10S)-11-(4-fluorophenoxy)-1,10-dihydroxyundeca-2,4,8-trien-6-yn-1-yl)-1,4-dioxan-2-one (compound (1)), which is a lactone-containing analog of lipoxin A4 (LXA4). In particular, the invention features pharmaceutical compositions including compound (1) and the use of compound (1) for the treatment of a disorder (e.g., a fibrotic disorder or an inflammatory disorder, such as an autoimmune disorder) in a subject in need thereof.

Abstract: The invention relates to cannabinoid compounds, pharmaceutical compositions including one or more cannabinoid compounds, and the use of pharmaceutical compositions including one or more cannabinoid compounds for the treatment of a disease or condition (e.g., a fibrotic disease or an inflammatory disease) in a subject in need thereof.